SFI
ZYNE

Susquehanna Fundamental Investments’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-27,336
Closed -$90K – 1650
2020
Q4 		$90K Sell
27,336
-31,032
-53% -$118K ﹤0.01% 1432
2020
Q3 		$193K Buy
58,368
+28,768
+97% +$106K 0.01% 1204
2020
Q2 		$100K Buy
+29,600
New +$140K ﹤0.01% 904

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna Fundamental Investments's ZYNE Position: Q1 2021 in Review

Susquehanna Fundamental Investments sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2021, closing a stake of 27,336 shares — an estimated $90K sold.

Susquehanna Fundamental Investments first reported a position in ZYNE in Q2 2020 and held it in 3 quarters. The position peaked at $193K in Q3 2020. 67 funds tracked by Wall St. Rank hold ZYNE as of Q1 2021.

  • Susquehanna Fundamental Investments reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 27,336 Zynerba Pharmaceuticals, Inc shares in Q1 2021, an estimated $90K.
  • Susquehanna Fundamental Investments first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2020 and held it in 3 quarters.
  • Susquehanna Fundamental Investments's Zynerba Pharmaceuticals, Inc position peaked at $193K in Q3 2020.
  • 67 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2021, filed 17 May 2021.